A biotech company was developing a PCR-based assay to screen for the pathogens behind hundreds of infectious diseases. They found that DNA contamination from host cells in most commercially available Taq polymerase could lead to false findings as well as a need in performance requirement for their highly sensitive assays. After evaluating enzymes from several suppliers, they came to Thermo Fisher Scientific for custom solution to meet their performance criteria.
Watch the video from Todd Howren, Commercial Supply Business Lead, describing the development of enzymes using a proprietary technology called molecular in vitro evolution. This technology enables the introduction and selection of multiple favorable mutations into a wild-type enzyme, resulting in performance improvements of enzyme function. With these engineered enzymes, molecular DNA-based assay design and development can be improve drastically and further differentiate for various pathogens and sample types.
Interested in a custom solution? Contact us at MDxenzymes@thermofisher.com